Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.46 |
| ▸ | NOS3 | P29474 | 5/20 | 0.44 |
| ▸ | NOS1 | P29475 | 5/20 | 0.44 |
| ▸ | NOS2 | P35228 | 5/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 5/20 | 0.43 |
| ▸ | FNTB | P49356 | 5/20 | 0.43 |
| ▸ | PGGT1B | P53609 | 4/20 | 0.43 |
| ▸ | BHMT | Q93088 | 2/20 | 0.40 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL15194117 | 1.00 | OTC (0.46) | OTCNOS3NOS1NOS2CYP2C19 | |
| Arginine SCHEMBL1766047 | 1.00 | OTC (0.46) | OTCNOS3NOS1NOS2CYP2C19 | |
| Arginine SCHEMBL9234547 | 1.00 | OTC (0.46) | OTCNOS3NOS1NOS2CYP2C19 | |
| Arginine SCHEMBL13684847 | 1.00 | OTC (0.46) | OTCNOS3NOS1NOS2CYP2C19 | |
| Arginine SCHEMBL27597219 | 0.96 | OTC (0.43) | OTCNOS3NOS1NOS2CYP2C19 | |
| Arginine SCHEMBL27729914 | 0.95 | OTC (0.42) | OTCNOS3NOS1NOS2CYP2C19 | |
| Arginine SCHEMBL27696870 | 0.95 | GSR (0.45) | OTCNOS3NOS1NOS2CYP2C19 | |
| Arginine SCHEMBL6514018 | 0.95 | OTC (0.42) | OTCNOS3NOS1NOS2CYP2C19 | |
| Arginine SCHEMBL27896158 | 0.95 | OTC (0.42) | OTCNOS3NOS1NOS2CYP2C19 | |
| Arginine SCHEMBL18660568 | 0.93 | ALOX15 (0.49) | OTCNOS3NOS1NOS2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1292615-B1 | MODIFIED MORBILLIVIRUS V PROTEINS | WYETH CORP (US) | 2006-10-25 | — | — | EP | claimed |
| US-6664066-B2 | Mutant measles virus V protein; gene expression and engineering | WYETH HOLDINGS CORPORATION | 2003-12-16 | — | — | US | claimed |
| US-20030206925-A1 | MODIFIED MORBILLIVIRUS V PROTEINS | WYETH HOLDINGS CORPORATION | 2003-11-06 | — | — | US | claimed |
| WO-1999048923-A1 | MULTIVALENT LIGANDS WHICH MODULATE ANGIOGENESIS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1999-09-30 | — | — | WO | claimed |
| US-20210024600-A1 | RECOMBINANT FILAGGRIN POLYPEPTIDES FOR CELL IMPORTATION | RESEARCH DEVELOPMENT FOUNDATION (US) | 2021-01-28 | — | — | US | disclosed |
| US-10336797-B2 | Recombinant filaggrin polypeptides for cell importation | RESEARCH DEVELOPMENT FOUNDATION (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190127430-A1 | RECOMBINANT FILAGGRIN POLYPEPTIDES FOR CELL IMPORTATION | RESEARCH DEVELOPMENT FOUNDATION (US) | 2019-05-02 | — | — | US | disclosed |
| EP-2522720-B1 | MUTANT STRAIN FOR PRODUCING L-ORNITHINE OR L-ARGININE, AND METHOD FOR PRODUCING SAME | CJ CHEILJEDANG CORP (KR) | 2018-03-28 | — | — | EP | disclosed |
| EP-2504357-B1 | RECOMBINANT FILAGGRIN POLYPEPTIDES FOR CELL IMPORTATION | RES DEV FOUNDATION (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-3179977-A1 | DEODORIZING AND SKIN CLEANING | Nevada Naturals, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| WO-2016024999-A1 | DEODORIZING AND SKIN CLEANING | NEVADA NATURALS INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| US-20140349903-A1 | DEODORIZING AND SKIN CLEANING | NEVADA NATURALS INC. | 2014-11-27 | — | — | US | disclosed |
| WO-2004080920-A1 | HYDROPONIC PLANT NUTRIENT KIT AND METHOD OF USE | ADVANCED NUTRIENTS LTD. (CA) | 2004-09-23 | — | — | WO | disclosed |
| US-6664066-B2 | Mutant measles virus V protein; gene expression and engineering | WYETH HOLDINGS CORPORATION | 2003-12-16 | — | — | US | disclosed |
| US-20030206925-A1 | MODIFIED MORBILLIVIRUS V PROTEINS | WYETH HOLDINGS CORPORATION | 2003-11-06 | — | — | US | disclosed |
| EP-1064358-A2 | MUTATIONS RESPONSIBLE FOR ATTENUATION IN MEASLES VIRUS OR HUMAN RESPIRATORY SYNCYTIAL VIRUS SUBGROUP B | AMERICAN CYANAMID COMPANY (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-1999049017-A2 | MUTATIONS RESPONSIBLE FOR ATTENUATION IN MEASLES VIRUS OR HUMAN RESPIRATORY SYNCYTIAL VIRUS SUBGROUP B | AMERICAN CYANAMID COMPANY (US) | 1999-09-30 | — | — | WO | disclosed |
| CN-1180312-A | Anti-obesity proteins | ELI LILILY AND CO (US) | 1998-04-29 | — | — | CN | disclosed |
| EP-0546108-A4 | PRO-DRUGS FOR CCK ANTAGONISTS | — | 1993-09-22 | — | — | EP | disclosed |
| EP-0546108-A1 | PRO-DRUGS FOR CCK ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1993-06-16 | — | — | EP | disclosed |